Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

SANUWAVE to present preclinical research of PACE technology

SANUWAVE Health, a developer of noninvasive devices for the repair and regeneration of vascular structures, is set to unveil the preclinical research related to biologic mechanisms of pulsed acoustic cellular expression (PACE) technology.

The preclinical research of PACE technology was conducted by Maria Siemionow at Cleveland clinic.

PACE technology delivers acoustic pressure waves in the shock wave spectrum to produce compressive and tensile stresses on cells and tissue structures to promote angiogenic (blood vessel formation) and positive inflammatory responses, and initiate the healing cascade.

PACE treatment resulted in an increase in arterial and venule diameters and the number of functional capillaries, which suggests an increase in blood perfusion that is known to benefit the healing of ischemic conditions.

Pre- and postischemic PACE treatment also suppressed expression of numerous proinflammatory factors, which has been shown to positively influence the healing process.

SANUWAVE president and CEO Christopher Cashman said in addition to demonstrating positive PACE effects of the vascular system, the Cleveland Clinic researchers also showed that PACE inhibits inflammation.